1. Introduction {#sec0005}
===============

Diglycolic acid (DGA) is present in the U.S. food supply as an indirect additive from the use of carboxymethyl cellulose (CMC). CMCs are used as binding agents in dietary supplement tablets and thickeners in other processed food products [@bib0005]. Typical food products found to contain DGA include frozen dairy products, cake baking mixes, syrups, and glazes. It is the chemical process of CMC synthesis in which condensing glycolic acid with monochloroacetic acid produces DGA as a reaction byproduct [@bib0010]. DGA remains in the final CMC reaction product as an impurity that cannot be easily removed [@bib0015].

The DGA exposure level to consumers is currently unknown. Actual data on exposure levels are lacking and will require comprehensive analytical studies using large sample sizes of numerous types and brands of food products. DGA is suspected to be a renal toxicant based on the toxicity of diethylene glycol (DEG) and its metabolism into DGA [@bib0020], [@bib0025]. Reports by others [@bib0030], [@bib0035] have also indicated that DGA is a renal toxicant based on *in vitro* and rat *in vivo* research with diethylene glycol, whose metabolism *in vivo* generates DGA. Research by Landry et al. [@bib0035] has indicated that inhibition of a key citric acid cycle enzyme, succinate dehydrogenase, can occur, along with a decrease in cellular respiration and an increase in reactive oxygen species (ROS) following DGA exposure in human proximal tubule cells. Excess ROS levels can lead to a number of kidney-related pathologies, including DNA damage, protein modification, and lipid peroxidation [@bib0040], [@bib0045], [@bib0050]. A single case report of accidental ingestion of DGA by a human also demonstrated the potency of DGA in causing kidney damage [@bib0055].

Given the potential for DGA to induce kidney damage, we sought to carry out two main goals. First, to evaluate the effect of its direct exposure of human kidney cells using the *in vitro* model cell line HK-2. This cell line carries many phenotypic and functional characteristics of primary renal cells and has been shown to be a useful model for *in vitro* evaluation of several renal toxicants [@bib0060], [@bib0065], [@bib0070]. We used several *in vitro* techniques to capture multiple facets of DGA-induced nephrotoxicity including both cellular and mitochondrial toxicity, as well as Luminex detection of the FDA-approved biomarker of nephrotoxicity Kidney Injury Molecule-1 (KIM-1) [@bib0075]. Expression of KIM-1 has been shown to become the most highly upregulated protein in settings where proximal tubule cells are injured. This biomarker may also play a role in the regeneration of proximal tubules following injury [@bib0080].

As our second goal, we sought to determine whether our *in vitro* model correlated with a rat *in vivo* model of DGA toxicology. As a subset of a recent *in vivo* study [@bib0085], we measured the same kidney-specific biomarker measured in the HK-2 system in the urine of rats exposed to DGA. Our *in vitro* and *in vivo* findings yielded strikingly similar findings. Extending our *in vitro* assessments to the *in vivo* setting is a highly valuable to the FDA and to industry. Understanding the value of *in vitro* modeling to predict *in vivo* outcomes for future compounds of interest can help accelerate the pace of toxicology research.

2. Materials and methods {#sec0010}
========================

2.1. Cell culture and treatments {#sec0015}
--------------------------------

HK-2 cells were grown in keratinocyte-SFM media supplemented with 5% FBS, recombinant human EGF, and bovine pituitary extract (Invitrogen, Carlsbad, CA) at 37 °C in a 5% CO~2~ humidified atmosphere, following similar culture conditions to when this cell line was established [@bib0090]. Viable cells were counted by Trypan blue dye (Invitrogen) exclusion via hemocytometer and seeded at a density of 2 × 10^4^ cells per 100 ul per well in 96-well plates (Corning, New York, NY). Peripheral wells of 96-well plates were filled with 100 ul of sterile water to help reduce media evaporation in the inner wells. Serially diluted stock treatment solutions of Diglycolic acid (Sigma, St. Louis, MO), nephrotoxicant (positive control) *cis*-diamineplatinum(II) dichloride (cisplatin) (Sigma), and nephroprotectant (negative control) valproic acid (Sigma) were made by weighing out their powders, dissolving them in cell culture media and diluting this mixture with media to achieve serial dilutions ranging from 0 mM to 10 mM. Chemically treated cells were incubated in triplicate for 24 h.

2.2. Cytotoxicity assay {#sec0020}
-----------------------

CellTiter-Glo Cell Viability Assay (Promega, Madison, WI) was used to determine the cytotoxicity of DGA relative to cisplatin and valproic acid. This luminescence-based method establishes cellular levels of ATP, which is directly proportional to cell viability. Following manufacturer's instructions, cells were treated in black-wall, clear bottom 96-well plates and when ready for the assay, plates were equilibrated to room temperature for 30 min, during which time water in the outer wells were replaced with 100 ul of treatment or media only controls. CellTiter-Glo working solution (100 ul) was added to each well. Plates were put on an orbital shaker for 2 min to induce cell lysis and then incubated for an additional 10 min before being read on an OMG Fluorostar Omega plate reader (BMG LABTECH, Ortenberg, Germany) to determine the levels of luminescence emitted from each well.

2.3. Reactive oxygen species assay {#sec0025}
----------------------------------

The levels of reactive oxygen species (ROS) were determined using the ROS-Glo H~2~O~2~ luminescence-based detection system (Promega) and data were normalized to cell viability. Cells treated with DGA, cisplatin, or valproic acid were incubated with H~2~O~2~ substrate for the remaining 5 h of their 24-h treatment at 37 °C in a 5% CO~2~ humidified atmosphere. The Detection Reagent was added and samples were incubated at room temperature for at least 20 min. Luminescence was read on an BMG Fluorostar Omega plate reader.

2.4. Mitochondrial membrane potential assay {#sec0030}
-------------------------------------------

The ratiometric dye JC-10 (Enzo, Farmingdale, NY) was utilized to evaluate changes in mitochondrial membrane potential (MMP). A stock solution of 400 uM JC-10 was made by mixing JC-10 lyophilized powder with 1 ml of HBSS. A working solution of JC-10 was then made by diluting the stock solution by 20-fold for a final concentration of 20 uM. Treated cells were labeled with dye for 2 h, washed twice in HBSS and then overlaid with 100 ul of HBSS. Plates were read using an BMG Fluorostar Omega plate reader to measure emission at 520 and 590 nm following excitation at 485 nm. Background auto-fluorescence levels from treatments or media alone were insignificant.

2.5. Luminex biomarker assay {#sec0035}
----------------------------

Culture supernatants from cells treated in vitro for 24 h with DGA, cisplatin, and valproic acid at doses of 0--10 mM were evaluated for levels of Kidney Injury-1 (KIM-1) using the Human Kidney Toxicity kit (Bio-Rad, Hercules, CA). For comparison, urine samples from an *in vivo* study [@bib0085] were also tested for KIM-1 levels. All animals from which urine samples were collected were maintained and handled under IACUC-approved protocols. As described in detail in Sprando et al. [@bib0085], urine samples were collected from female Sprague Dawley rats treated daily by oral gavage with DGA at doses of 0, 0.3, 1.0, 3.0, 10.0, 30.0, 100.0 and 300.0 mg/kg of body weight (bw) for 28 days (or sooner, if euthanasia was deemed necessary). Following the manufacturer's protocol, all samples were blocked in their plates with 10 ul of blocking reagent for 1 h and washed two times using the Bioplex plate washer (Bio-Rad). Sample, standard, and control volumes of 30 ul were added to their pre-designated wells and incubated for 1 h. Plates were washed and 30 ul of detection antibody were added for a final incubation of 30 min. Plates were given a final wash with buffer and read using a Luminex 200 instrument (Bio-Rad). Biomarker expression levels were normalized to cell viability.

2.6. Statistics {#sec0040}
---------------

Software programs Microsoft Excel and Prism (GraphPad, San Diego, CA) were used to perform data calculations and analyses, respectively. Student *t*-tests or 2-way ANOVAs were used to determine whether dose-matched DGA effects in our described assays were statistically significant from the effects of control compounds (valproic acid and cisplatin) at P values less than 0.05, as indicated.

3. Results {#sec0045}
==========

3.1. Exposure of kidney cells to DGA *in vitro* is associated with significant cell death {#sec0050}
-----------------------------------------------------------------------------------------

To investigate the effect of DGA on kidney cell viability, we exposed human proximal tubule cells, HK-2, to increasing doses of DGA and compared these effects to exposing HK-2 cells to control compounds: cisplatin and valproic acid (positive and negative controls, respectively). The cell viability assay we employed measures ATP levels since ATP production decreases as cells undergo cell death. As shown in [Fig. 1](#fig0005){ref-type="fig"}, we found that whereas our negative control, valproic acid, did not induce measurable cell death between the treatment concentrations of 0--10 mM, our positive control, cisplatin, exhibited a rapid decrease in ATP production beginning at the low exposure concentration of 0.5 mM after 24 h of treatment, as expected. Interestingly, DGA started out having an innocuous effect between the treatment concentrations of 0--2.5 mM, but proceeded towards cytotoxicity at 5 mM; cell viability was significantly lower than that of valproic acid-treated cells (P \< 0.05), but higher than that of cisplatin-treated cells (P \< 0.05). As the DGA concentration was increased, cell viability of DGA-treated continued to decrease sharply at concentrations to levels similar to cisplatin-treated cells. Further analysis of these results yielded lethal concentration 50 (LC~50~) values for DGA to be 4.0 mM, which is intermediary to that of cisplatin (0.4 mM) and valproic acid (41.7 mM). In an effort to verify these results, we used an alternative technique to determine if DGA was inducing HK-2 cell death, as opposed to interfering with the chemical aspect of the ATP assay. Calcein AM is a well-accepted method of cell viability detection which relies of the ability of live cells to cleave non-fluorescent Calcein AM dye into a fluorescent molecule. As shown in Supplementary Fig. S1, increasing levels of DGA and cisplatin both decrease the levels of live cells, confirming our ATP assay findings.Fig. 1Cell viability of HK-2 cells sharply decreases with increasing doses of DGA. HK-2 cells were treated with DGA (closed triangles), cisplatin (open squares), or valproic acid (open circles) at concentrations ranging from 0 to 10 mM for 24 h. ATP luminescence assay was used to quantitate the relative levels of HK-2 cell viability. Data shown is representative of three independent experiments. \*, P \< 0.05, DGA vs. control treatment (cisplatin or valproic acid).Fig. 1

3.2. DGA induces dose-dependent mitochondrial toxicity in HK-2 cells {#sec0055}
--------------------------------------------------------------------

To investigate the involvement of mitochondria in the cytotoxic effect of DGA, we used two main approaches. First, we investigated the extent to which the mitochondrial populations lost their membrane potential (MMP) in response to DGA exposure relative to valproic acid or cisplatin exposure. A widely accepted method utilizes the dye JC-10, which selectively enters membrane-compromised mitochondria and fluoresces at 520 nm, while JC-10 dye molecules that are excluded from intact mitochondria fluoresce at 590 nm. Staining HK-2 cells with JC-10 after 24 h of treatment with DGA, cisplatin, or valproic acid showed that DGA could indeed exert mitochondrial toxicity onto HK-2 cells ([Fig. 2](#fig0010){ref-type="fig"}a). Below the concentration of 5 mM, the ratio of mitochondria with lost vs. maintained MMP remained low following exposure to valproic acid and DGA. At the treatment concentration of 5 mM or above, this ratio significantly increased (P \< 0.05) in DGA-treated cells, but not valproic acid-treated cells. By contrast, the relative levels of mitochondrial populations whose MMP were lost actually increased starting from 0.05 mM of cisplatin. In excess of 5 mM of treatment, DGA and cisplatin achieved indistinguishable levels of compromised to intact mitochondria. We used the alternative approach of staining DGA-treated HK-2 cells with resazurin in order to help corroborate our findings. As shown in Supplementary Fig. S2, the mitochondrial reductase activity that resazurin detects shows decreasing mitochondrial activity as DGA treatment concentration increases.Fig. 2Effects of DGA on mitochondrial integrity and reactive oxygen species production in HK-2 cells. Cells treated with DGA (closed triangles), cisplatin (open squares), or valproic acid (open circles) were assayed for (a) relative levels of mitochondria that have undergone loss vs. maintenance of their membrane potential (MMP) and (b) levels of ROS normalized to cell viability. Changes in MMP were calculated as a ratio of fluorescence emission at 520 nm:590 nm. Data shown is representative of three independent experiments. \*, P \< 0.05, DGA vs. control treatment (cisplatin or valproic acid).Fig. 2

To explore the reason for the observed mitochondrial toxicity associated with DGA, we next determined whether elevations in reactive oxygen species (ROS) were taking place in treated HK-2 cells. The oxidative stress associated with such elevations could help account for mitotoxicity. As shown in [Fig. 2](#fig0010){ref-type="fig"}b, we determined that not only did elevations in ROS levels take place in DGA-treated HK-2 cells, but the trend of this elevation took place at the exact treatment concentrations that we measured in our investigation of MMP loss shown in [Fig. 2](#fig0010){ref-type="fig"}a. Specifically, DGA treatment induced a spike in ROS production at concentrations of 5 mM and above relative to valproic acid (P \< 0.05). By contrast, valproic acid produced no measurable change in ROS levels between the whole range of 0--10 mM while cisplatin treatment was associated with potent ROS release starting at 0.5 mM treatment reaching levels of DGA-induced ROS production above 5 mM.

3.3. Kidney-specific toxicity determination of DGA *in vitro* and *in vivo* {#sec0060}
---------------------------------------------------------------------------

We used the highly sensitive Luminex technique of measuring kidney-specific damage to HK-2 cells using the biomarker Kidney Injury Molecule-1 (KIM-1). KIM-1 is an FDA-qualified biomarker for nephrotoxicity as it is expressed at increasing levels by proximal tubule cells as cellular damage takes place. In our *in vitro* cellular system, we found that exposing HK-2 cells for 24 h to DGA induced a measurable increase in KIM-1 expression that became statistically significant beyond the 5 mM exposure dose (P \< 0.05) as shown in [Fig. 3](#fig0015){ref-type="fig"}. Our negative control valproic acid did not cause an elevated KIM-1 levels, but negative control cisplatin was associated with a rise in KIM-1 starting from 0.05 mM treatment concentration. Interestingly, KIM-1 induction by DGA appeared to exceed that of cisplatin at the high doses of 7.5 mM and 10 mM (P \< 0.05).Fig. 3Luminex assay of nephrotoxicity biomarker expression levels in HK-2 cells exposed to DGA. Cell culture supernatants taken from HK-2 cells exposed to DGA, cisplatin, or valproic acid were analyzed for levels of Kidney Injury Molecule 1 (KIM-1). Biomarker expression levels were normalized to cell viability. Data shown was taken three independent experiments. \*, P \< 0.05, DGA vs. control treatment (cisplatin or valproic acid). \*, control (cisplatin or valproic acid) vs. DGA, P \< 0.05.Fig. 3

In an effort to corroborate our *in vitro* findings, we sought to compare our results to the levels of KIM-1 in urine samples collected from rats that have been treated with increasing doses of DGA. As described in a separate manuscript [@bib0085], rats were orally gavaged daily with a range of increasing concentrations of DGA solutions or vehicle control solution for up to 28 days. As shown in [Fig. 4](#fig0020){ref-type="fig"}a, urine samples were tested for KIM-1 by Luminex after 2, 4, 8, 16, and 22 days post-exposure. DGA induced its expression in the highest dose cohort of animals (300 mg/kg bw) after merely 2 days of exposure to DGA. The animals in this cohort stopped urinating by Day 4 post-DGA exposure and needed to be euthanized by Day 5, thereby preventing longer-term urine samples to be assayed for KIM-1 levels. However, the cohort of animals that received 100 mg/kg bw did survive beyond the 22 day post-exposure time point and produced enough urine for KIM-1 level determination. We found that KIM-1 expression significantly increased after 4 days of DGA exposure (100 mg/kg bw) relative to vehicle control (P \< 0.05) and that this level decreased over time. The remaining groups of animals receiving 30 mg/kg bw DGA or less did not exhibit any significant changes in KIM-1 expression ([Fig. 4](#fig0020){ref-type="fig"}a).Fig. 4Analysis of nephrotoxicity biomarker levels present in urine samples of rats exposed to DGA. (a) KIM-1 levels in rat urine collected from rats treated with increasing levels of DGA after 2, 4, 8, 16, and 22 days of DGA exposure. (b) Analysis of KIM-1 levels in urine collected from vehicle control and maximum DGA exposure cohorts (0 and 300 mg/kg bw, respectively). \*, P \< 0.05, DGA vs. vehicle control treated animals. 'X' symbol in graphs indicate the lack of urine available for analysis from the 300 mg/kg bw cohort, which was euthanized at Day 5 post-treatment.Fig. 4

In order to further investigate the kinetics of KIM-1 elevation in the 300 mg/kg bw dose cohort, a second rat study was performed where animals were either orally gavaged daily with vehicle control solution or 300 mg/kg bw of DGA [@bib0085]; manuscript under review). Urine samples were collected from animals after 1, 2, 3, or 4 days post-DGA administration and assayed for KIM-1 levels. As shown in [Fig. 4](#fig0020){ref-type="fig"}b, the increase in KIM-1 began after just 2 days post-DGA exposure and continued to increase until reaching statistical significance at Day 3 post-DGA exposure (P \< 0.05). As expected, the lack of urine output at Day 4 post-DGA prevented urinary KIM-1 evaluation.

4. Discussion {#sec0065}
=============

Identifying potential toxicity related to food additives is an important part of ensuring the safety of the U.S. food supply. Although CMCs themselves may have limited toxicity, their unavoidable contamination by their byproduct DGA raises the question of its safety. Until recently, evidence pointing to kidney toxicity by DGA remained sparse; one human case of fatal poisoning [@bib0055] and two reports of DEG causing renal toxicity due to its metabolite DGA [@bib0020], [@bib0025] were published. New interests in DGA resurfaced with the publication of recent *in vitro* and *in vivo* research showing that DEG is nephrotoxic on account of its liver-derived metabolite, DGA [@bib0030], [@bib0035]. As part of a larger effort to directly examine the safety of DGA for the FDA, we began with an *in vitro* model system using HK-2 cell line. We selected the HK-2 cell line as our cellular *in vitro* model for its ability to closely mimic both morphological and metabolic features of primary human proximal tubule cells [@bib0090]. HK-2 cells express epithelial cell biomarkers and brush border enzymes that are specific to proximal tubules [@bib0090]. Although we did not evaluate the effects of DGA on primary proximal tubule cells from human donors, several other investigators have successfully used the HK-2 cell line to show that it can reliably and accurately model *in vivo* injury when exposed to well-established nephrotoxicants, including cisplatin, further supporting its use as a cellular *in vitro* model [@bib0065], [@bib0095], [@bib0100]. The data we generated using cisplatin and valproic acid as our positive and negative controls, respectively, in this study are consistent with the findings of other researchers using HK-2 cells [@bib0105], [@bib0065]. Having both a positive and negative control allowed us to gauge the toxicity of DGA from two points of view.

Our study using the HK-2 *in vitro* model revealed four main findings. First, HK-2 exposure to DGA was acutely and dose-dependently cytotoxic at a level that was intermediary between the innocuous valproic acid and the highly toxic cisplatin. Second, this apparent cytotoxicity correlates with our evidence of oxidative stress mechanisms involving over-production of reactive oxygen species and loss of mitochondrial integrity. Indeed, high ROS production can lead to mitochondrial damage [@bib0110], which in turn can prevent cellular respiration for maintained viability. Whether the correlation between cytotoxicity and increased ROS levels is causative remains to be fully investigated. Reports by Landry et al. [@bib0115] and Conrad et al. [@bib0150] show that the reduction of DGA-induced ROS by antioxidants does not prevent mitochondria from becoming dysfunctional, suggesting that ROS elevations may simply be a secondary effect. The third major finding of our study was that DGA cytotoxicity elicited strong KIM-1 expression. The sensitive detection Luminex technique we used captured the production of this important biomarker, in response to increasing doses of DGA treatment. Finally, this biomarker was also increased in our *in vivo* system, specifically in the two highest dose animal cohorts within a short time of initiating their exposure to DGA. The elevation of KIM-1 specifically reflect proximal tubule damage *in vivo* [@bib0120], [@bib0125], as well as damaged HK-2 cells [@bib0060], [@bib0065], [@bib0070].

Our comparison of DGA nephrotoxicity *in vitro* to *in vivo* is a unique and important aspect of this study. The two systems complement each other well and validate the idea that *in vitro* systems can be used for preliminary extrapolation of an *in vivo* outcome. The *in vitro* approach is relatively rapid and inexpensive and reveals key mechanistic details, but leaves doubt regarding its utility in predicting *in vivo* models. Herein, we address this issue by first establishing that DGA is nephrotoxic *in vitro* and using Luminex biomarker detection to relate the *in vitro* to *in vivo* findings. That the two systems were consistent in indicating DGA nephrotoxicity not only validates HK-2 cells as a useful predictor for the *in vivo* results, but calls for more research to be done to compare the predictability of HK-2 cells in predicting the nephrotoxicity of other compounds on proximal tubule cells.

Although the nephrotoxicity of DGA was evidently revealed by our two model systems, it does not seem clear whether it is possible to accurately conclude exactly how toxic DGA is *in vivo* based on our *in vitro* data. Exposing HK-2 cells to DGA treatment solutions of varying strengths offers a sense of how toxic DGA is relative to our chosen control compounds. However, the question of how these concentrations translate to *in vivo* dosing remains unanswered. Quantitative analyses of DGA levels in the kidneys of rats treated with DGA or even DEG like those performed in Robinson et al. [@bib0155] and Landry et al. [@bib0130], respectively, would assist in helping to establish how *in vivo* dosing translates to renal exposure and hence give a better understanding of the *in vivo* state. Additional studies would be also be needed to better understand how ingested DGA can translate to *in vivo* blood levels and how these components enter the blood and get filtered through the glomerulus for further exposure to the proximal tubules.

This gap in understanding the translation of *in vitro* to *in vivo* dosing is further complicated by the notion that DGA is a notoriously difficult byproduct to extract out of CMC products [@bib0015]. This difficulty implies that if DGA is present in food as a contaminant of a food additive, then it raises the question of how readily would it be released *in vivo* following ingestion. DGA is present in food at very low concentrations [@bib0135] and that it likely takes very high doses of DGA to induce the toxicity we observed *in vivo* [@bib0085]. If DGA remains bound to CMC molecules, then the question of how would its nephrotoxicity profile change becomes less relevant. *In vivo* studies using DGA mixed into animal feed, for example, would help address this question. Further research towards understanding what the actual levels of exposure are to U.S. consumers is also critical to gaining a better perspective of how realistic it would be for an average consumer to be exposed to effective doses of DGA that would cause proximal tubule cell damage.

Ultimately, the balance between safety and risks associated with DGA will depend on many factors, including the long-term vs. short-term exposure to DGA, the concentration and frequency of exposure, and the reversibility of any chronic or acute kidney damage. It should be noted that although our study focused on the effects of DGA on renal systems, the potential for DGA to target other organ systems, exists. As such, we have also investigated the toxicity of direct exposure of DGA on the liver (manuscript submitted) and the heart [@bib0140]. Other publications have also demonstrated DGA-induced liver toxicity in animal models (Robinson et al., 2017, [@bib0085]). In humans, the aforementioned case report of accidental ingestion of DGA includes a description of its injurious effects on kidneys, liver and brain [@bib0055]. Moreover, the mass-population DEG poisoning in Panama also led to damage in these organs [@bib0145]. Of note, studies demonstrating neuronal toxic effects by DGA have yet to be performed.

Taken together, the results of our study support the idea that DGA is nephrotoxic in a dose-dependent manner and may exert its effects through a mitochondrial mechanism. Our collective data highlights the utility of the HK-2 *in vitro* system for the purpose of predicting *in vivo* toxicity outcomes. This study also underscores the value of performing *in vitro* research in parallel with *in vivo* research. As more data is gathered in such comparative studies, quantitative meta-analyses will become feasible to help determine the predictability of specific *in vitro* systems for animal and even human outcomes.
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